HA121 28
Alternative Names: HA-121-28Latest Information Update: 15 Feb 2023
At a glance
- Originator CSPC ZhongQi Pharmaceutical Technology
- Class Antineoplastics; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists; Proto-oncogene protein c-ret inhibitors; Vascular endothelial growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Biliary cancer; Non-small cell lung cancer; Thyroid cancer
- Phase I Solid tumours
Most Recent Events
- 02 Feb 2023 CSPC ZhongQi Pharmaceutical Technology terminates a phase II trial in Biliary cancer (In adults, In the elderly, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO) as primary endpoint not meeting expectations(NCT04784520)
- 03 Mar 2022 CSPC ZhongQi Pharmaceutical Technology completes a phase I trial in Healthy volunteers in China (PO) (NCT05072535)
- 18 Feb 2022 Phase-II clinical trials in Non-small cell lung cancer (Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in China (PO) (NCT05117658)